# US 2014/0155380 A1 · Salt and Crystalline Forms Thereof of a Drug

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0155380 A1
- Document ID: US20140155380A1
- Status: Published application
- Kind: A1
- Application number: 14/175,621
- Filed: 2014-02-07
- Published: 2014-06-05
- Earliest claimed: 2004-10-08
- Assignees: AbbVie Inc.
- Applicants: Abbvie Inc.
- Inventors: Geoff G.Z. ZHANG; Michael F. BRADLEY; David M. BARNES; Rodger HENRY
- Web page: https://patentgrep.com/patent/US20140155380A1

## CPC

- C07D 401/14: containing three or more hetero rings
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 47/02: Inorganic compounds
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61P 31/04: Antibacterial agents
- C07C 31/26: Hexahydroxylic alcohols
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

A crystalline form of a drug, ways to make it, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.

## Claims

### Claim 1

A therapeutic composition comprising D-Glucitol, 1-deoxy-1-(methylamino)-, 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-1,4-dihydro-7-(3-hydroxyazetidin-1-yl)-4-oxo-3-quinolinecarboxylate salt, at least one filler, at least one binder, at least one disintegrating agent, at least one buffering agent and at least one lubricant.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the salt is present in a therapeutically acceptable amount.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the salt is crystalline.

### Claim 4 (depends on 3)

The composition of claim 3, wherein the salt has substantial crystalline purity.

### Claim 5 (depends on 4)

The composition of claim 4, wherein the salt has at least about 95% crystalline purity.

### Claim 6 (depends on 3)

The composition of claim 3, wherein the salt is characterized, when measured at about 25° C. with Cu—Kα radiation, by the powder diffraction pattern shown in FIG. 1.

### Claim 7 (depends on 3)

The composition of claim 3, wherein the salt is characterized by respective lattice parameters, a, b, and c of about 16.4460 Å, 21.4010 Å, and 5.3050 Å and β of about 109° in the monoclinic crystal system P 21/C or P 21/M space group, when measured with Mo—Kα radiation at about 25° C.

### Claim 8 (depends on 1)

The composition of claim 1, wherein the salt has substantial chemical purity.

### Claim 9 (depends on 8)

The composition of claim 8, wherein the salt is about 97% chemically pure.

### Claim 10 (depends on 8)

The composition of claim 8, wherein the salt is about 98% chemically pure.

### Claim 11 (depends on 8)

The composition of claim 8, wherein the salt is about 100% chemically pure.

### Claim 12 (depends on 1)

The composition of claim 1, wherein the composition is an orally administered dosage form.

### Claim 13 (depends on 1)

The composition of claim 1, wherein the at least one filler comprises cellulose.

### Claim 14 (depends on 1)

The composition of claim 1, wherein the at least one binder comprises povidone.

### Claim 15 (depends on 1)

The composition of claim 1, wherein the at least one disintegrating agent comprises cross-povidone.

### Claim 16 (depends on 1)

The composition of claim 1, wherein the at least one buffering agent comprises a sodium phosphate salt.

### Claim 17 (depends on 1)

The composition of claim 1, wherein the at least one buffering agent comprises a citrate.

### Claim 18 (depends on 1)

The composition of claim 1, wherein the at least one lubricant comprises magnesium stearate.

### Claim 19 (depends on 1)

The composition of claim 1, wherein the at least one filler comprises cellulose, the at least one binder comprises povidone, the at least one disintegrating agent comprises cross-povidone, the at least one buffering agent comprises a sodium phosphate salt, and the at least one lubricant comprises magnesium stearate.

### Claim 20 (depends on 19)

The composition of claim 19, further comprising a citrate.

### Claim 21

A therapeutic composition comprising D-Glucitol, 1-deoxy-1-(methylamino)-, 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-1,4-dihydro-7-(3-hydroxyazetidin-1-yl)-4-oxo-3-quinolinecarboxylate salt, cellulose, povidone, cross-povidone, a sodium phosphate salt and magnesium stearate.

### Claim 22 (depends on 21)

The therapeutic composition of claim 21, further comprising a citrate.

### Claim 23

A method of treating a bacterial infection in a fish or a mammal comprising administering thereto a composition comprising a therapeutically acceptable amount of D-Glucitol, 1-deoxy-1-(methylamino)-, 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-1,4-dihydro-7-(3-hydroxyazetidin-1-yl)-4-oxo-3-quinolinecarboxylate salt, at least one filler, at least one binder, at least one disintegrating agent, at least one buffering agent and at least one lubricant.

### Claim 24 (depends on 21)

The method of claim 21, wherein the composition is administered to a mammal.

### Claim 25 (depends on 21)

The method of claim 21, wherein the therapeutically acceptable amount is from about 0.03 to about 200 mg/kg body weight.

### Claim 26 (depends on 21)

The method of claim 21, wherein the at least one filler comprises cellulose.

### Claim 27 (depends on 21)

The method of claim 21, wherein the at least one binder comprises povidone.

### Claim 28 (depends on 21)

The method of claim 21, wherein the at least one disintegrating agent comprises cross-povidone.

### Claim 29 (depends on 21)

The method of claim 21, wherein the at least one buffering agent comprises a sodium phosphate salt.

### Claim 30 (depends on 21)

The method of claim 21, wherein the at least one buffering agent comprises a citrate.

### Claim 31 (depends on 21)

The method of claim 21, wherein the at least one lubricant comprises magnesium stearate.

### Claim 32 (depends on 21)

The method of claim 21, wherein the at least one filler comprises cellulose, the at least one binder comprises povidone, the at least one disintegrating agent comprises cross-povidone, the at least one buffering agent comprises a sodium phosphate salt, and the at least one lubricant comprises magnesium stearate.

### Claim 33 (depends on 32)

The method of claim 32, further comprising a citrate.

### Claim 34

A method of treating a bacterial infection in a fish or a mammal comprising administering thereto a composition comprising a therapeutically acceptable amount of D-Glucitol, 1-deoxy-1-(methylamino)-, 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-1,4-dihydro-7-(3-hydroxyazetidin-1-yl)-4-oxo-3-quinolinecarboxylate salt, at least one filler, cellulose, povidone, cross-povidone, a sodium phosphate salt and magnesium stearate.

### Claim 35 (depends on 34)

The method of claim 34, further comprising a citrate.
